Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12385411 | 1.00 | NOS1 (1.00) | NOS1NOS3 | |
| SCHEMBL12385410 | 0.91 | NOS1 (0.83) | NOS1NOS3 | |
| SCHEMBL2600820 | 0.91 | NOS1 (0.83) | NOS1NOS3 | |
| SCHEMBL2600828 | 0.90 | NOS1 (0.81) | NOS1NOS3 | |
| SCHEMBL12385630 | 0.90 | NOS1 (0.81) | NOS1NOS3 | |
| SCHEMBL10049815 | 0.90 | NOS1 (0.81) | NOS1NOS3 | |
| SCHEMBL10049830 | 0.90 | NOS1 (0.81) | NOS1NOS3 | |
| SCHEMBL12385640 | 0.80 | NOS1 (0.74) | NOS1NOS3 | |
| SCHEMBL10050015 | 0.80 | NOS1 (0.74) | NOS1NOS3 | |
| SCHEMBL2114438 | 0.78 | NOS1 (0.63) | NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642282-B2 | Inhibitors of nitric oxide synthase for treatment of melanoma | NORTHWESTERN UNIVERSITY (US) | 2014-02-04 | — | — | US | claimed |
| US-20120238016-A1 | Specific nNOS Inhibitors for the Therapy And Prevention Of Human Melanoma | NORTHWESTERN UNIVERSITY | 2012-09-20 | — | — | US | claimed |
| US-9090589-B2 | Specific nNOS inhibitors for the therapy and prevention of human melanoma | NORTHWESTERN UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140147920-A1 | Specific nNOS Inhibitors for the Therapy and Prevention of Human Melanoma | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-29 | — | — | US | disclosed |
| US-8642282-B2 | Inhibitors of nitric oxide synthase for treatment of melanoma | NORTHWESTERN UNIVERSITY (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120238016-A1 | Specific nNOS Inhibitors for the Therapy And Prevention Of Human Melanoma | NORTHWESTERN UNIVERSITY | 2012-09-20 | — | — | US | disclosed |
| WO-2012097121-A2 | SPECIFIC NNOS INHIBITORS FOR THE THERAPY AND PREVENTION OF HUMAN MELANOMA | NORTHWESTERN UNIVERSITY (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20090104677-A1 | Heteroaromatic Selective Inhibitors of Neuronal Nitric Oxide Synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-23 | — | — | US | disclosed |
| US-7470790-B2 | Heteroaromatic selective inhibitors of neuronal nitric oxide synthase | NORTHWESTERN UNIVERSITY (US) | 2008-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140147920-A1 | Specific nNOS Inhibitors for the Therapy and Prevention of Human Melanoma | NOS3, NOS1, NOS2 | NOS1 2/4885NOS3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.